| Year |
Citation |
Score |
| 2018 |
D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, ... ... Meyronet D, et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nature Medicine. PMID 30531922 DOI: 10.1038/S41591-018-0263-8 |
0.31 |
|
| 2017 |
Royet A, Broutier L, Coissieux MM, Malleval C, Gadot N, Maillet D, Gratadou-Hupon L, Bernet A, Nony P, Treilleux I, Honnorat J, Liebl D, Pelletier L, Berger F, Meyronet D, et al. Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. Oncotarget. 8: 23750-23759. PMID 28423606 DOI: 10.18632/Oncotarget.16077 |
0.364 |
|
| 2016 |
Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D. Molecular heterogeneity of glioblastomas: does location matter? Oncotarget. 7: 902-13. PMID 26637806 DOI: 10.18632/Oncotarget.6433 |
0.311 |
|
| 2016 |
Frappaz D, Chinot OL, Meyronet D, Garin G, Laigle-Donadey F, Rhun EL, Levard Ab, Frenel J, Idbaih A, Gourmelon C, Homisco K, Hottinger A, Remir E, Jaouen L, Arbault C, et al. MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2083 |
0.309 |
|
| 2015 |
Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur ME, Besançon R, Naudet N, Magadoux L, Khanna R, Ducray F, Meyronet D, et al. CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. Cancer Research. 75: 3519-28. PMID 26122847 DOI: 10.1158/0008-5472.Can-14-0631 |
0.742 |
|
| 2015 |
Meyronet D, Dorey A, Massoma P, Rey C, Alix E, Silva K, Perrin C, Quadrio I, Perret-Liaudet A, Streichenberger N, Thomasset N, Honnorat J, Arzberger T, Kretzschmar H. The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. Journal of Neural Transmission (Vienna, Austria : 1996). 122: 975-91. PMID 25976431 DOI: 10.1007/S00702-015-1378-4 |
0.657 |
|
| 2015 |
Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Reports. 11: 577-91. PMID 25892230 DOI: 10.1016/J.Celrep.2015.03.055 |
0.335 |
|
| 2013 |
Brot S, Malleval C, Benetollo C, Auger C, Meyronet D, Rogemond V, Honnorat J, Moradi-Améli M. Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. Experimental Cell Research. 319: 588-99. PMID 23298946 DOI: 10.1016/J.Yexcr.2012.12.011 |
0.359 |
|
| 2008 |
Meyronet D, Massoma P, Thivolet F, Chalabreysse L, Rogemond V, Schlama A, Honnorat J, Thomasset N. Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. The American Journal of Surgical Pathology. 32: 1699-708. PMID 18769332 DOI: 10.1097/Pas.0B013E31817Dc37C |
0.667 |
|
| 2005 |
Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (New York, N.Y.). 7: 457-65. PMID 15967098 DOI: 10.1593/Neo.04721 |
0.34 |
|
| 2004 |
Bagnard D, Sainturet N, Meyronet D, Perraut M, Miehe M, Roussel G, Aunis D, Belin MF, Thomasset N. Differential MAP kinases activation during semaphorin3A-induced repulsion or apoptosis of neural progenitor cells. Molecular and Cellular Neurosciences. 25: 722-31. PMID 15080899 DOI: 10.1016/J.Mcn.2003.12.007 |
0.577 |
|
| Show low-probability matches. |